Holen Sie sich die Stockscreener-App
21.18
5.27%
1.06
Handel nachbörslich:
21.18
Schlusskurs vom Vortag:
$20.12
Offen:
$19.91
24-Stunden-Volumen:
1.91M
Relative Volume:
0.73
Marktkapitalisierung:
$3.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-5.487
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
+12.72%
1M Leistung:
+26.45%
6M Leistung:
+80.10%
1J Leistung:
-28.76%
1-Tages-Spanne:
$19.67
$21.24
1-Wochen-Bereich:
$18.42
$22.00
52-Wochen-Spanne:
$6.36
$31.32
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
21.18 | 2.87B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Why Dyne Therapeutics Stock Was Crushing it This Week - The Globe and Mail
Will Dyne Therapeutics Inc. stock see PE expansionMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Why Dyne Therapeutics Inc. stock is favored by top institutions - newser.com
Can Dyne Therapeutics Inc. stock reach $100 price targetWall Street Watch & Low Drawdown Investment Ideas - newser.com
Is Dyne Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explained2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Will Dyne Therapeutics Inc. stock deliver better than expected guidanceQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
Will Dyne Therapeutics Inc. stock go up soon2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territoryIPO Watch & Reliable Breakout Forecasts - newser.com
Historical volatility pattern of Dyne Therapeutics Inc. visualized2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Dyne Therapeutics Inc. stock volume spike explainedInflation Watch & High Return Trade Guides - newser.com
Technical Reactions to DYN Trends in Macro Strategies - news.stocktradersdaily.com
Technical analysis overview for Dyne Therapeutics Inc. stock2025 Macro Impact & Low Drawdown Momentum Ideas - newser.com
Why Dyne Therapeutics Inc. stock is seen as undervalued2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Dyne Therapeutics Inc Stock Analysis and ForecastHigh Dividend Yield Stocks & Outstanding Portfolio Tips - earlytimes.in
Baird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
JP Morgan Maintains Dyne Therapeutics (DYN) Neutral Recommendation - Nasdaq
Dyne Therapeutics price target lowered to $17 from $18 at JPMorgan - MSN
JP Morgan Lowers Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
What drives Dyne Therapeutics Inc stock priceLong-Term Investment Plans & Free Tap Rapid Wealth - earlytimes.in
How moving averages guide Dyne Therapeutics Inc. tradingJuly 2025 Final Week & Free Community Consensus Stock Picks - newser.com
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):